Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

Junko Tanizaki(Kindai University Sakai Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital)

British Journal of Cancer

August 16, 2011

10.1038/bjc.2011.322

Cited by 120

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

|New England Journal of Medicine|2014|3.2k

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

|Journal of Clinical Oncology|2011|1.6k

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2017|1.2k

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

|JAMA Oncology|2017|1k